Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ)

· seekingalpha.com

Cullinan Therapeutics (CGEM) stock jumps as lung cancer drug zipalertinib with chemotherapy succeeds in late-stage trial. Read more here.

Cullinan Therapeutics (CGEM) added ~6% in the premarket on Thursday after the Cambridge, Massachusetts-based biotech and its partner Taiho Pharmaceutical announ...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI